Gregory A Eschenauer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/464720/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tocilizumab for Treatment of Mechanically Ventilated Patients With COVID-19. Clinical Infectious Diseases, 2021, 73, e445-e454.	2.9	350
2	Comparison of echinocandin antifungals. Therapeutics and Clinical Risk Management, 2007, 3, 71-97.	0.9	164
3	Epidemiology, Clinical Characteristics and Outcomes of Extensively Drug-Resistant Acinetobacter baumannii Infections among Solid Organ Transplant Recipients. PLoS ONE, 2012, 7, e52349.	1.1	118
4	Carbapenem-resistant Klebsiella pneumoniae bacteremia: factors correlated with clinical and microbiologic outcomes. Diagnostic Microbiology and Infectious Disease, 2010, 67, 180-184.	0.8	92
5	Risk Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients. JAMA Internal Medicine, 2019, 179, 1519.	2.6	82
6	Antifungal prophylaxis in liver transplant recipients. Liver Transplantation, 2009, 15, 842-858.	1.3	64
7	Targeted Versus Universal Antifungal Prophylaxis Among Liver Transplant Recipients. American Journal of Transplantation, 2015, 15, 180-189.	2.6	64
8	Real-World Experience with Echinocandin MICs against Candida Species in a Multicenter Study of Hospitals That Routinely Perform Susceptibility Testing of Bloodstream Isolates. Antimicrobial Agents and Chemotherapy, 2014, 58, 1897-1906.	1.4	59
9	Pharmacology and therapeutic uses of theanine. American Journal of Health-System Pharmacy, 2006, 63, 26-30.	0.5	49
10	Fluconazole versus an echinocandin for Candida glabrata fungaemia: a retrospective cohort study. Journal of Antimicrobial Chemotherapy, 2013, 68, 922-926.	1.3	42
11	Antifungal Prophylaxis in Lung Transplant Recipients. Transplantation, 2016, 100, 1815-1826.	0.5	35
12	A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia. Journal of Antimicrobial Chemotherapy, 2018, 73, 1402-1407.	1.3	32
13	Impact of an antimicrobial stewardship-led intervention forStaphylococcus aureusbacteraemia: a quasi-experimental study. Journal of Antimicrobial Chemotherapy, 2015, 70, dkv256.	1.3	30
14	Evolving role of early antifungals in the adult intensive care unit. Critical Care Medicine, 2009, 37, 1580-1593.	0.4	28
15	To Test or Not To Test: a Cost Minimization Analysis of Susceptibility Testing for Patients with Documented Candida glabrata Fungemias. Journal of Clinical Microbiology, 2007, 45, 1884-1888.	1.8	27
16	The impact of delaying the initiation of appropriate antifungal treatment for <i>Candida</i> bloodstream infection. Medical Mycology, 2010, 48, 436-439.	0.3	27
17	Doripenem MICs andompK36Porin Genotypes of Sequence Type 258, KPC-Producing Klebsiella pneumoniae May Predict Responses to Carbapenem-Colistin Combination Therapy among Patients with Bacteremia. Antimicrobial Agents and Chemotherapy, 2015, 59, 1797-1801.	1.4	25
18	Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia. Annals of Pharmacotherapy, 2015, 49, 1068-1074.	0.9	25

GREGORY A ESCHENAUER

#	Article	IF	CITATIONS
19	The Evolving Role of Antifungal Susceptibility Testing. Pharmacotherapy, 2013, 33, 465-475.	1.2	22
20	Bringing the "Power" to Cerner's PowerChart for Antimicrobial Stewardship. Clinical Infectious Diseases, 2014, 59, 416-424.	2.9	19
21	Disease-based antimicrobial stewardship: a review of active and passive approaches to patient management. Journal of Antimicrobial Chemotherapy, 2017, 72, 3232-3244.	1.3	18
22	Are In Vitro Susceptibilities to Azole Antifungals Predictive of Clinical Outcome in the Treatment of Candidemia?. Journal of Clinical Microbiology, 2018, 56, .	1.8	13
23	Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients. Journal of Fungi (Basel, Switzerland), 2021, 7, 76.	1.5	12
24	Survival in Patients with Candida glabrata Bloodstream Infection Is Associated with Fluconazole Dose. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
25	Dose Timing of Aminoglycosides in Hemodialysis Patients: A Pharmacology View. Seminars in Dialysis, 2016, 29, 204-213.	0.7	10
26	Effect of an antimicrobial stewardship intervention on outcomes for patients with Clostridium difficile infection. American Journal of Infection Control, 2016, 44, 1539-1543.	1.1	10
27	Incorporating preauthorization into antimicrobial stewardship pharmacist workflow reduces Clostridioides difficile and gastrointestinal panel testing. Infection Control and Hospital Epidemiology, 2020, 41, 1136-1141.	1.0	6
28	Supratherapeutic oseltamivir levels during continuous dialysis: an expected risk. Intensive Care Medicine, 2011, 37, 371-371.	3.9	5
29	Evolution of Equations for Estimating Renal Function and Their Application to the Dosing of New Antimicrobials. Annals of Pharmacotherapy, 2020, 54, 496-503.	0.9	4
30	Azithromycin-Warfarin Interaction: Are We Fishing with a Red Herring?. Pharmacotherapy, 2005, 25, 630-631.	1.2	3
31	Antibiotic Allergy. New England Journal of Medicine, 2006, 354, 2293-2294.	13.9	3
32	Calming the "Perfect Storm" in Methicillin-Resistant Staphylococcus aureus Bacteremia: A Call for a More Balanced Discussion. Clinical Infectious Diseases, 2015, 60, 670-671.	2.9	3
33	Monoclonal Antibodies for Early Treatment of COVID-19 in a World of Evolving SARS-CoV-2 Mutations and Variants. Open Forum Infectious Diseases, 2021, 8, ofab268.	0.4	3
34	Compliance with Institutional Guidelines on the Use of Vancomycin in a Medical Intensive Care Unit. Hospital Pharmacy, 2006, 41, 749-753.	0.4	2
35	Macrolideâ€resistant Mycoplasma pneumoniae pneumonia in transplantation: Increasingly typical?. Transplant Infectious Disease, 2020, 22, e13318	0.7	2
36	578. Infections in Patients Treated with Chimeric Antigen Receptor T-cells (CAR-T) therapy. Open Forum Infectious Diseases, 2020, 7, S354-S354.	0.4	2

#	Article	IF	CITATIONS
37	1071. Impact of Standard vs. Prolonged Courses of Antibiotics for the Treatment of Uncomplicated Staphylococcus aureus Bacteremia (SAB) in Patients With Hematologic Malignancies. Open Forum Infectious Diseases, 2018, 5, S320-S321.	0.4	1
38	869. Evaluation of Broad-Spectrum Antibiotic De-Escalation in Patients with Health-Care Associated Pneumonia (HCAP) and No Microbiological Diagnosis. Open Forum Infectious Diseases, 2018, 5, S23-S24.	0.4	1
39	AÂMulticenter Stewardship Initiative to Decrease Excessive Duration of Antibiotic Therapy for the Treatment of Community-Acquired Pneumonia (CAP). Open Forum Infectious Diseases, 2017, 4, S63-S64.	0.4	0
40	1876. Patient- and Hospital-Level Factors and Outcomes Associated With Treatment of Asymptomatic Bacteriuria in Hospitalized Patients: A Multi-Hospital Cohort Study. Open Forum Infectious Diseases, 2018, 5, S536-S537.	0.4	0
41	2152. Epidemiology and Clinical Outcomes of Contemporary, Third-Generation Left Ventricular Assist Device (LVAD) Infections. Open Forum Infectious Diseases, 2018, 5, S634-S634.	0.4	0
42	1035. Implementation of an Antimicrobial Stewardship Program-Led, Multifactorial Pneumonia Diagnosis and Treatment Bundle. Open Forum Infectious Diseases, 2019, 6, S364-S364.	0.4	0
43	1056. Evaluation of Clinical Outcomes Following Implementation of Real-Time Stewardship Team Interventions for Multi-Drug-Resistant Organisms. Open Forum Infectious Diseases, 2019, 6, S373-S373.	0.4	0
44	Antifungal stewardship: Still catching up? Commentary on "Variability in antifungal stewardship strategies among Society for Healthcare Epidemiology of America (SHEA) Research Network facilities― Infection Control and Hospital Epidemiology, 2020, 41, 590-591.	1.0	0
45	792. Evaluation of Persistent Diarrhea and Recurrence Following Fecal Microbiota Transplantation for Recurrent <i>Clostridioides difficile</i> Infection. Open Forum Infectious Diseases, 2020, 7, S439-S440.	0.4	0